DGX

Business profile & competitive position

Quest Diagnostics Incorporated (DGX) operates in the Healthcare sector, specifically the Medical - Diagnostics & Research industry. Its core Diagnostic Information Services segment turns laboratory testing into clinical insights for patients, physicians, and organizations, while the smaller Diagnostic Solutions segment offers risk assessment services to insurers and healthcare IT solutions to providers and payers. In 2025, the company generated $11.0 billion in net revenue and processed approximately 244 million test requisitions. Its physical network spans roughly 2,400 patient service centers, about 8,000 patient access points, and a logistics operation that makes more than 83,000 stops daily. Quest reports that it serves approximately one-third of U.S. adults annually and reaches about half of U.S. physicians and half of U.S. hospitals each year.

The financial profile frames the competitive question in concrete terms: a 9.5% net margin and 15.2% ROE suggest the company converts scale into returns above those of many capital-intensive healthcare peers. In a business where payers and providers value reach, turnaround, and test-menu breadth, high volume and dense geographic access are meaningful structural advantages. Margin and ROE alone do not prove durable pricing power, but they do show that, at its current scale, Quest is earning abnormal returns relative to generic capital.

Financial posture

Quest currently trades with a market capitalization of $26.8 billion, a P/E ratio of 23.9, a net margin of 9.5%, and an ROE of 15.2%. The stock's beta is 0.54, indicating materially lower market sensitivity than the average stock, consistent with a defensive, recurring-revenue healthcare services profile. A P/E of 23.9 is not inexpensive in absolute terms, but when set against 15.2% ROE and a stable 9.5% net margin it reads more like a premium paid for resilience than for speculative growth. The current share price is $242.95, sitting above a 50-day EMA of $234.42, with an RSI of 60.3 that is neither overbought nor oversold.

Strategic priorities & outlook

The company's own most recent 10-K filing lays out a clear operational agenda. Growth is expected to come from offering an industry-leading test menu and collaborating with healthcare providers and partners to leverage broad patient access. Acquisitions are described as a value-creating growth lever, but only under disciplined investment criteria. Quest also intends to use data assets and services to improve population health and enable value-based care. On the cost side, efficiency is expected to come from the Quest Management System, automation, artificial intelligence, and the Invigorate cost excellence program.

These priorities can be measured against past execution. With $11.0 billion in 2025 net revenue and 244 million test requisitions, volume growth, acquisition integration, and cost-per-test improvement are likely the most practical lenses through which investors will track progress. The strategic emphasis on data also introduces a direct operational risk tied to security and privacy, a theme that has recently moved from theoretical to headline material.

Macro & geopolitical exposure

As a large U.S.-focused diagnostic services provider, Quest sits in a segment shaped primarily by reimbursement policy, Medicare/Medicaid pricing, commercial insurer contracting, and broad healthcare regulation. Diagnostic labs are exposed to changes in fee schedules, prior-authorization rules, and any federal legislation affecting coverage or pricing transparency. Because the business depends on physical specimen logistics and laboratory reagent supply chains, disruptions in transport, labor, or imported consumables can affect turnaround times and margins. Data security regulation — including HIPAA and state breach-notification laws — is also a direct operating risk for any company handling medical records at scale.

Recent developments

Late October 2026 brought four revealing headlines. On October 26, defenseworld.net reported that Yousif Capital Management LLC raised its holdings in Quest Diagnostics. On October 23, TechCrunch and BusinessWire both reported that Quest had confirmed a data breach involving patients' personal and health data, and AWKO Law LLP announced an investigation into the incident the same day. Also on October 23, Zacks published a piece asking why Quest Diagnostics is a top momentum stock for the long term.

Taken together, the news highlights the central tension around the stock: an institutional buyer adding shares on one side, and a cybersecurity and privacy event generating legal and media attention on the other. For a company whose strategy explicitly leans on leveraging data assets, the breach carries regulatory, reputational, and trust dimensions that can influence provider and payer relationships.

Earnings behavior & post-earnings drift

Quest has beaten analyst EPS estimates in all of the last eight reported quarters, a 100% beat rate, with an average earnings surprise of 4.2%. Despite that consistency, the average 5-day price move following earnings across those quarters is -0.84%, classified as a slight downward drift.

The most recent report, on October 22, 2026, delivered EPS of $3 against an estimate of $2.87, a 4.5% beat. The stock fell 0.57% the next session and was flat (0%) over the following five days. The July 23, 2026 quarter produced a much larger 10.6% surprise, yet the next-day move was -0.02% and the five-day drift was +2.81%. The April 21, 2026 quarter was a 5.5% beat but led to a -0.51% next-day move and a -4.87% five-day drift. The February 10, 2026 report, while a narrower 2.5% beat, actually rose 1.93% the next day before drifting -0.47% over the next five sessions.

This pattern suggests that Quest's headline beats are often priced in ahead of the release; the market's real expectation may sit above the published consensus. For the upcoming report scheduled for February 9, 2027, before the open, the current consensus EPS estimate is $2.68. Those watching the unofficial consensus should note that beating the published number has not reliably produced follow-through, and that much of the post-earnings price action has hinged on guidance and commentary rather than the EPS beat alone.

For traders and investors who want a fuller picture of how institutional research houses, options positioning, and quantitative models are sizing up this stock ahead of the February 9, 2027 report, the full institutional verdict on the ticker page is the next logical stop.